Nasdaq: $29.63 (+0.33) | AIM: £4.32 (-0.06)
新聞中心及演示文稿
上一篇文章   |   下一篇文章
監管信息公告, 腫瘤學 / 免疫學 | 2007-11-22

Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients